WallStreetZenWallStreetZen

NASDAQ: INTS
Intensity Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their INTS stock forecasts and price targets.

Forecast return on equity

Is INTS forecast to generate an efficient return?

Company
159.72%
Industry
61.77%
Market
168.43%
INTS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INTS forecast to generate an efficient return on assets?

Company
134.52%
Industry
30.53%
INTS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INTS earnings per share forecast

What is INTS's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$4.02
Avg 2 year Forecast
-$4.34
Avg 3 year Forecast
-$5.37

INTS revenue forecast

What is INTS's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$53.5M

INTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INTS$5.21N/AN/A
MBRX$2.56$22.00+759.38%Buy
JUNS$0.38N/AN/A
BCDA$1.14N/AN/A
BIVI$1.65N/AN/A
View Top Biotech Stocks

Intensity Therapeutics Stock Forecast FAQ

What is INTS's earnings growth forecast for 2026-2028?

(NASDAQ: INTS) Intensity Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.1%.

Intensity Therapeutics's earnings in 2026 is -$11,606,000.On average, 7 Wall Street analysts forecast INTS's earnings for 2026 to be -$10,218,471, with the lowest INTS earnings forecast at -$11,203,684, and the highest INTS earnings forecast at -$7,602,500. On average, 6 Wall Street analysts forecast INTS's earnings for 2027 to be -$11,026,102, with the lowest INTS earnings forecast at -$12,473,435, and the highest INTS earnings forecast at -$9,336,404.

In 2028, INTS is forecast to generate -$13,643,344 in earnings, with the lowest earnings forecast at -$17,627,130 and the highest earnings forecast at -$9,203,026.

If you're new to stock investing, here's how to buy Intensity Therapeutics stock.

What is INTS's revenue growth forecast for 2026-2028?

(NASDAQ: INTS) Intensity Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.71%.

Intensity Therapeutics's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast INTS's revenue for 2026 to be $0, with the lowest INTS revenue forecast at $0, and the highest INTS revenue forecast at $0. On average, 5 Wall Street analysts forecast INTS's revenue for 2027 to be $0, with the lowest INTS revenue forecast at $0, and the highest INTS revenue forecast at $0.

In 2028, INTS is forecast to generate $135,905,010 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $279,812,653.

What is INTS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: INTS) forecast ROA is 134.52%, which is higher than the forecast US Biotechnology industry average of 30.53%.

What is INTS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: INTS) Intensity Therapeutics's current Earnings Per Share (EPS) is -$8.56. On average, analysts forecast that INTS's EPS will be -$4.02 for 2026, with the lowest EPS forecast at -$4.41, and the highest EPS forecast at -$2.99. On average, analysts forecast that INTS's EPS will be -$4.34 for 2027, with the lowest EPS forecast at -$4.91, and the highest EPS forecast at -$3.68. In 2028, INTS's EPS is forecast to hit -$5.37 (min: -$6.94, max: -$3.62).

What is INTS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: INTS) forecast ROE is 159.72%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.